Quick Answer
Xtant Medical Holdings, Inc. reported Total Revenue of $133.93 million for fiscal year 2025.
Xtant Medical Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $133.93M +14.2% |
$117.27M +28.4% |
$91.30M +57.5% |
$57.97M +4.9% |
$55.26M +3.6% |
$53.34M -17.5% |
| Revenue (ASC 606) | $133.93M +14.2% |
$117.27M +28.4% |
$91.30M +57.5% |
$57.97M +4.9% |
$55.26M +3.6% |
$53.34M -17.5% |
| Net Income | $4.97M +130.2% |
-$16.45M -2592.3% |
$660.0K +107.8% |
-$8.48M -75.0% |
-$4.85M +31.0% |
-$7.02M +14.6% |
| Diluted EPS | $0.03 +125.0% |
-$0.12 -1300.0% |
$0.01 +111.1% |
-$0.09 -50.0% |
-$0.06 +76.0% |
-$0.25 +60.3% |
| Total Assets | $94.14M +0.3% |
$93.84M +1.3% |
$92.61M +53.8% |
$60.23M +10.1% |
$54.69M +31.9% |
$41.47M -3.9% |
| Cash and Equivalents | $17.05M +175.1% |
$6.20M +8.5% |
$5.71M -71.8% |
$20.30M +11.3% |
$18.24M +679.3% |
$2.34M -55.3% |
| Long-Term Debt | $11.03M -50.0% |
$22.04M +28.4% |
$17.17M +77.2% |
$9.69M -17.8% |
$11.79M | — |
| Stockholders Equity | $50.95M +18.6% |
$42.96M -16.3% |
$51.35M +50.3% |
$34.17M +10.6% |
$30.88M +112.8% |
$14.51M +132.8% |
| R&D Expense | $2.10M -11.9% |
$2.38M +78.5% |
$1.34M +46.0% |
$915.0K +5.2% |
$870.0K +32.4% |
$657.0K -29.5% |
| Operating Income | $7.28M +160.3% |
-$12.07M -18.9% |
-$10.16M -50.4% |
-$6.75M -75.3% |
-$3.85M -413.2% |
-$751.0K +66.7% |
| Gross Profit | $84.27M +23.5% |
$68.22M +23.0% |
$55.47M +72.6% |
$32.14M -1.1% |
$32.49M -5.5% |
$34.39M -19.1% |
| Shares Outstanding | 140.04M +0.7% |
139.05M +6.8% |
130.18M +19.6% |
108.87M +25.0% |
87.07M +12.2% |
77.57M +489.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $33.26M | +19.0% | -6.1% |
| Revenue (ASC 606) | September 30, 2025 | $33.26M | +19.0% | -6.1% |
| Net Income | September 30, 2025 | $1.31M | +126.0% | -63.2% |
| Diluted EPS | September 30, 2025 | $0.01 | +125.0% | -50.0% |
| Total Assets | September 30, 2025 | $106.32M | +7.5% | +2.7% |
| Cash and Equivalents | September 30, 2025 | $10.40M | +57.7% | +50.2% |
| Long-Term Debt | September 30, 2025 | $17.40M | -9.1% | -21.9% |
| Stockholders Equity | September 30, 2025 | $50.38M | +10.2% | +3.9% |
| R&D Expense | September 30, 2025 | $634.0K | -9.6% | +12.0% |
| Operating Income | September 30, 2025 | $2.54M | +167.3% | -45.0% |
| Gross Profit | September 30, 2025 | $21.99M | +34.9% | -9.4% |
| Shares Outstanding | September 30, 2025 | 140.00M | +1.0% | +0.5% |
- Xtant Medical Holdings, Inc. reported Total Revenue of $133.93 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +14.2% in Total Revenue compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Revenue (ASC 606) of $133.93 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +14.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Net Income of $4.97 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +130.2% in Net Income compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Diluted EPS of $0.03 per share for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +125.0% in Diluted EPS compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Total Assets of $94.14 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +0.3% in Total Assets compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Cash and Equivalents of $17.05 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +175.1% in Cash and Equivalents compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Long-Term Debt of $11.03 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed a decrease of -50.0% in Long-Term Debt compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Stockholders Equity of $50.95 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +18.6% in Stockholders Equity compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported R&D Expense of $2.10 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed a decrease of -11.9% in R&D Expense compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Operating Income of $7.28 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +160.3% in Operating Income compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Gross Profit of $84.27 million for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +23.5% in Gross Profit compared to the prior fiscal year.
- Xtant Medical Holdings, Inc. reported Shares Outstanding of 140.04 million shares for fiscal year 2025.
- Xtant Medical Holdings, Inc. showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: